Innovent Biologics' (HKG:1801) IBI363 medication for immunotherapy-resistant non-small cell lung cancer and wild-type lung adenocarcinoma showed a manageable safety profile, efficacy, and long-term survival benefits during its phase 1 study.
The drug company presented the findings during the 2025 American Society of Clinical Oncology Conference, according to a Wednesday news release.
IBI363 also showed breakthrough therapeutic potential from tumor response to long-term survival benefits for patients with immuno-resistant squamous non-small cell lung cancer, and wild-type lung adenocarcinoma, especially with those who smoked.
Shares surged 14% during Wednesday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。